Medtronic announces Infuse spine trial

By

Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures.

The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, after the FDA approved a separate study in 2017 for posterolateral fusion procedures, which is still enrolling patients. If you want to read more about this news, click here. 

Posted in News.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    10 octubre, 2019

    AI-enhanced ECGs may soon assess overall health

    Scientists have trained an artificial intelligence tool to predict sex and estimate age from electrocardiogram readouts. They suggest that, with further development, the tool could soon be helping doctors to assess the overall health of their patients. An electrocardiogram, also known as an ECG or EKG, is a painless, simple test that records the electrical …

  •
    10 octubre, 2019

    Human trials could start soon on Adam’s 3D printed bone grafts

    Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year. Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology …

  •
    10 octubre, 2019

    Deep brain stimulation can be effective for severe depression

    Researchers who monitored people with deep brain stimulation implants for 8 years suggest that the treatment can benefit those with severe depression. Regulators in the United States have already approved deep brain stimulation for the treatment of Parkinson’s disease, epilepsy, essential tremor, and obsessive-compulsive disorder. The treatment involves implanting wires into the brain and a stimulator in the chest …

  •
    30 diciembre, 2019

    Medical Devices; Exemptions From Premarket Notification for Class I and Class II Devices

    «The Food and Drug Administration (FDA, Agency) identified a list of class I devices and class II devices that are now exempt from premarket notification requirements, subject to certain limitations. FDA published the lists of final determinations in accordance with procedures established by the 21stCentury Cures Act (Cures Act). Although each classification regulation for each …